The drug development process necessitates the comprehensive evaluation of a candidate’s therapeutic benefits alongside its potential risks. Benefit–risk assessments are central to this endeavour, ...

The tech sector had strong earnings, while more traditional sectors have lagged, so we’re positioning accordingly. The combination of elevated yields, a healthy corporate index, and robust liquidity ...

Many U.S. corporate pension plans have seen funding levels materially improve in recent years. Strong equity markets and higher rates have put many plans near or above 100% funded. This is a critical ...

MammaPrint effectively predicts chemotherapy benefit and distant recurrence-free interval in HR+HER2- early breast cancer. High-risk patients benefit significantly from chemotherapy, while low-risk ...